Comparison of activated clotting times obtained using Hemochron and Medtronic analysers in patients receiving anti-thrombin therapy during cardiac catheterisation
暂无分享,去创建一个
[1] W. Chandler,et al. Monitoring direct thrombin inhibitors with a plasma diluted thrombin time , 2007, Thrombosis and Haemostasis.
[2] J. Ornato,et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). , 2006, Circulation.
[3] S. Spinler,et al. Anticoagulation Monitoring Part 2: Unfractionated Heparin and Low-Molecular-Weight Heparin , 2005, The Annals of pharmacotherapy.
[4] W. French,et al. Reproducibility and variability of activated clotting time measurements in the cardiac catheterization laboratory , 2005, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[5] Kadakia Ra,et al. Optimal antithrombotic treatment for percutaneous coronary intervention. , 2005 .
[6] S. Steinhubl,et al. Relationship Between Activated Clotting Time and Ischemic or Hemorrhagic Complications: Analysis of 4 Recent Randomized Clinical Trials of Percutaneous Coronary Intervention , 2004, Circulation.
[7] G. Dangas,et al. Percutaneous interventions in patients with immune-mediated heparin-induced thrombocytopenia. , 2004, Seminars in thrombosis and hemostasis.
[8] D. Sane,et al. Direct thrombin inhibitors in the treatment of immune-mediated heparin-induced thrombocytopenia. , 2004, Seminars in thrombosis and hemostasis.
[9] Deepak L. Bhatt,et al. Revisiting optimal anticoagulation with unfractionated heparin during coronary stent implantation. , 2003, The American journal of cardiology.
[10] J. Moses,et al. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin‐induced thrombocytopenia , 2002, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[11] J. Fareed,et al. Monitoring of Argatroban in ARG310 Study: Potential Recommendations for its Use in Interventional Cardiology , 2002, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
[12] H. Dauerman,et al. Activated Clotting Times in the Setting of Eptifibatide Use During Percutaneous Coronary Intervention , 2002, Journal of Thrombosis and Thrombolysis.
[13] Deepak L. Bhatt,et al. Defining the Optimal Activated Clotting Time During Percutaneous Coronary Intervention: Aggregate Results From 6 Randomized, Controlled Trials , 2001, Circulation.
[14] J. Ferguson. Conventional antithrombotic approaches. , 1995, American heart journal.
[15] R. Califf,et al. Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Platelet Integrin Glycoprotein IIb/IIIa Blocker Integrelin in Elective Coronary Intervention , 1995 .
[16] R. Califf,et al. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial) , 1995 .
[17] J. Ferguson,et al. The use of activated clotting times to monitor heparin therapy during and after interventional procedures , 1994, Clinical cardiology.
[18] J. Ferguson,et al. Comparison of Hemochron and HemoTec activated coagulation time target values during percutaneous transluminal coronary angioplasty. , 1994, Journal of the American College of Cardiology.
[19] D. Altman,et al. STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.
[20] B. Bull,et al. Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. , 1975, The Journal of thoracic and cardiovascular surgery.
[21] R. Yeh,et al. Argatroban: update. , 2006, American heart journal.
[22] J. Ferguson,et al. Optimal antithrombotic treatment for percutaneous coronary intervention. , 2005, Minerva cardioangiologica.
[23] S. Ellis,et al. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators. , 1995, Circulation.